ArticleFrontiers in endocrinology2026
Amniotic-fluid metabolomics identifies phospholipid remodeling as a metabolic signature of intrauterine exposure in pregnancies with polycystic ovary syndrome.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polycystic ovary syndrome is associated with metabolic and hormonal disturbances during pregnancy, but whether these alterations are reflected in the fetal intrauterine exposure environment remains incompletely understood. This study aimed to identify polycystic ovary syndrome-related intrauterine metabolic signatures using late-gestation amniotic fluid. Methods: Untargeted metabolomic profiling was performed on late-gestation amniotic fluid samples from women with polycystic ovary syndrome and controls. Differential metabolite analysis, pathway-level analysis, and multilevel sensitivity analyses were conducted to identify robust metabolic alterations associated with maternal polycystic ovary syndrome. Exploratory placental transcriptomic analysis and targeted RT-qPCR assessment in an independent sample set were further used to examine tissue-level molecular changes related to the lipidomic findings. Results: Amniotic fluid from pregnancies with polycystic ovary syndrome showed a distinct metabolic profile dominated by lipid remodeling. Differential metabolites were mainly enriched in membrane phospholipids, sphingolipid-related metabolites, polyunsaturated fatty acid-related pathways, and selected steroid hormone-related metabolites. Phospholipid remodeling was characterized by decreased phosphatidylcholine species, increased phosphatidylethanolamine species, a lower phosphatidylcholine/phosphatidylethanolamine ratio, and redistribution of arachidonic acid-containing phospholipids. Alpha-linolenic acid metabolism provided an additional polyunsaturated fatty acid-related signal. Sphingolipid enrichment suggested that lipid alterations extended from membrane structural remodeling to lipid-mediated signaling. Selected steroid hormone-related metabolites were also elevated, consistent with an altered hormonal milieu in pregnancies with polycystic ovary syndrome. These signatures remained largely stable across sensitivity analyses, as did the multivariable-adjusted inverse association between PE(16:0/20:4) and birth weight. Exploratory placental transcriptomic analysis and targeted RT-qPCR assessment in a small independent cohort provided preliminary tissue-level support for phospholipid-related molecular alterations, with the clearest changes involving PLA2-family genes and PCYT1A, suggesting cross-cohort convergence at the pathway level. Conclusions: These findings identify phospholipid remodeling as a major amniotic-fluid metabolic signature of polycystic ovary syndrome-related intrauterine exposure. PUFA-related metabolism, sphingolipid enrichment, and steroid hormone-related alterations provide additional metabolic context. Complementary placental molecular findings and the inverse association between PE(16:0/20:4) and birth weight further suggest potential links with the maternal-fetal interface and fetal growth. Further studies are needed to clarify the biological relevance of these changes and their potential role in offspring metabolic susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.